<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003199</url>
  </required_header>
  <id_info>
    <org_study_id>PSOC 1605</org_study_id>
    <secondary_id>NCI-2010-00728</secondary_id>
    <nct_id>NCT00003199</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer</brief_title>
  <official_title>A Phase II Trial for Patients With Inflammatory (Stage IIIB) and Responsive Metastatic Stage IV Breast Cancer Using Busulfan, Melphalan and Thiotepa Followed by Autologous or Syngeneic PBSC Rescue and 12 Weeks of Post-Engraftment Immunotherapy With Low-Dose IL-2 and GM-CSF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well giving combination chemotherapy and peripheral blood
      stem cell transplant followed by aldesleukin and sargramostim works in treating patients with
      inflammatory stage IIIB or metastatic stage IV breast cancer. Drugs used in chemotherapy,
      such as busulfan, melphalan, and thiotepa, work in different ways to stop the growth of tumor
      cells, either by killing the cells or by stopping them from dividing. A peripheral stem cell
      transplant may be able to replace blood-forming cells that were destroyed by chemotherapy.
      This may allow more chemotherapy to be given so that more tumor cells are killed. Aldesleukin
      may stimulate the white blood cells to kill breast cancer cells. Giving aldesleukin together
      with sargramostim may kill more tumor cells
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the event-free survival and survival of patients treated for inflammatory
      (Stage IIIb) and responsive stage IV breast cancer with BUMELTT and PBSC support and low dose
      immunotherapy with IL2 and GM-CSF.

      SECONDARY OBJECTIVES:

      II. To determine the toxicity of a combination of low-dose IL-2 and GM-CSF in patients
      following HDC with BUMELTT and PBSC support.

      OUTLINE:

      PREPARATIVE REGIMEN: Patients receive busulfan orally (PO) once every 6 hours on days -8, -7,
      and -6; melphalan IV over 30 minutes on days -5 and -4; and thiotepa IV over 2 hours on days
      -3 and -2.

      TRANSPLANTATION: Patients undergo autologous peripheral blood stem cell infusion on day 0.

      POST-TRANSPLANT THERAPY: All patients receive tamoxifen citrate* PO once daily beginning
      prior to aldesleukin (IL-2) and sargramostim (GM-CSF) therapy and continuing for 5 years or
      until relapse (estrogen receptor [ER]- or progesterone receptor [PR]-positive patients) OR
      until completion of IL-2/GM-CSF therapy (ER-negative or PR-negative patients). Eligible
      patients receive IL-2 subcutaneously (SC) daily and GM-CSF SC 3 times weekly for 12 weeks
      beginning 30-100 days after transplantation. Patients may receive radiotherapy after
      completion of IL-2/GM-CSF treatment if no prior radiotherapy was given before
      transplantation.

      *Stage IV patients not receiving IL-2/GM-CSF therapy who received tamoxifen citrate as part
      of adjuvant therapy and subsequently failed, receive oral anastrozole once daily for 5 years
      or until progression instead of tamoxifen.

      [*For postmenopausal patients, the choice and duration of hormonal therapy given in addition
      to or an alternative to tamoxifen therapy will be at the physician's discretion]

      Patients are followed up every 3 months for 2 years, every 6 months for 3 years, and then
      annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1997</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free Survival</measure>
    <time_frame>11 years</time_frame>
    <description>Event-free survival of patients treated for inflammatory (Stage IIIb) and responsive stage IV breast cancer with BUMELTT and PBSC support and low dose immunotherapy with IL2 and GM-CSF.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>11 years</time_frame>
    <description>Overall survival of patients treated for inflammatory (Stage IIIb) and responsive stage IV breast cancer with BUMELTT and PBSC support and low dose immunotherapy with IL2 and GM-CSF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Toxicity of a Combination of Low-dose IL-2 and GM-CSF</measure>
    <time_frame>16 Weeks</time_frame>
    <description>IL-2/GM-CSF toxicity assessed using the NCI Toxicity Criteria. Toxicity was defined as any grade 2, 3, 4 or 5 CNS (except grade 0-3 malaise and fatigue) toxicity; any grade 3, 4, or 5 non-CNS or non-hematological toxicity (except grade 0-3 bilirubin); or any grade 4 or 5 hematological toxicity.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Estrogen Receptor-negative Breast Cancer</condition>
  <condition>Estrogen Receptor-positive Breast Cancer</condition>
  <condition>Inflammatory Breast Cancer</condition>
  <condition>Male Breast Cancer</condition>
  <condition>Progesterone Receptor-negative Breast Cancer</condition>
  <condition>Progesterone Receptor-positive Breast Cancer</condition>
  <condition>Stage IIIB Breast Cancer</condition>
  <condition>Stage IV Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen citrate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Nolvadex</other_name>
    <other_name>TAM</other_name>
    <other_name>tamoxifen</other_name>
    <other_name>TMX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>BSF</other_name>
    <other_name>BU</other_name>
    <other_name>Misulfan</other_name>
    <other_name>Mitosan</other_name>
    <other_name>Myeloleukon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thiotepa</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Oncotiotepa</other_name>
    <other_name>STEPA</other_name>
    <other_name>TESPA</other_name>
    <other_name>Tespamin</other_name>
    <other_name>TSPA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Alkeran</other_name>
    <other_name>CB-3025</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-phenylalanine mustard</other_name>
    <other_name>L-Sarcolysin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>IL-2</other_name>
    <other_name>Proleukin</other_name>
    <other_name>recombinant human interleukin-2</other_name>
    <other_name>recombinant interleukin-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>GM-CSF</other_name>
    <other_name>Leukine</other_name>
    <other_name>Prokine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>Undergo autologous peripheral blood stem cell infusion</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSC transplantation</other_name>
    <other_name>peripheral blood progenitor cell transplantation</other_name>
    <other_name>transplantation, peripheral blood stem cell</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>May undergo radiotherapy after completion of IL-2/GM-CSF</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>irradiation</other_name>
    <other_name>radiotherapy</other_name>
    <other_name>therapy, radiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with inflammatory (stage IIIb) or responsive stage IV breast cancer with
             metastasis to soft tissue and/or bone; responsive stage IV disease is defined as
             patients who achieve a PR (&gt;= 50% reduction in measurable tumor burden) or CR
             following initial chemotherapy for metastatic disease or patients with locally
             recurrent disease (chest wall/axillary nodes) who are rendered disease-free following
             surgery or radiation therapy without receiving chemotherapy; bone disease is
             categorized as responsive if there is demonstrated sclerosis of prior lesions with no
             new lesions

          -  Patients should have received 4-7 cycles of an Adriamycin and/or taxane-based regimen
             for stage IIIb or stage IV disease; locally recurrent (chest wall/axillary nodes)
             patients rendered NED by RT or surgery do not need to receive chemotherapy for stage
             IV disease prior to Cytoxan/Taxol

          -  Patient has received Cytoxan 4 gm/m^2 x 1 and Taxol 250 mg/m^2 x 1 per FHCRC protocol
             506.03; Cytoxan/Taxol must be given after all other chemotherapy is completed and
             before transplant

          -  Stem cells were collected after mobilization with Cytoxan/Taxol or after mobilization
             from an FHCRC approved cytokine protocol; if syngeneic collection, PBSC's were
             collected by using G-CSF according to FHCRC protocol 753; patient has an adequate
             number of peripheral blood stem cells stored (&gt;= 2.5 x 10^6 CD34+ cells/kg)

          -  The patient must have the capacity to give informed consent; the patient must have
             signed an approved consent form conforming with federal and institutional guidelines

          -  Hepatic function: Bilirubin =&lt; 2 mg%; SGOT or SGPT =&lt; 2.5 x institutional normal

          -  Renal function: Creatinine =&lt; 2.0 mg/dl or a creatinine clearance &gt;= 50 mg/min

          -  Pre-Study tests have been performed as outlined in the Study Calendar

          -  Patients will begin IL-2/GM-CSF therapy if they meet the following criteria
             post-transplant:

          -  Can start therapy 30 to 100 days after transplant

          -  Karnofsky performance status &gt; 60

          -  ANC &gt; 1,000 cells/mm^3 and platelets &gt; 30,000/cells/mm^3 (transfusion independent) for
             at least 5 days before starting therapy

          -  Total bilirubin =&lt; 2.5 x upper limit of normal

          -  SGOT =&lt; 2.5 x upper limit of normal

          -  Creatinine =&lt; 2.0 mg/dl

        Exclusion Criteria:

          -  Patients with a Karnofsky Performance Score less than 70

          -  Patients with a left ventricular ejection fraction less than 50 % (LVEF must be
             performed in patients with symptoms of CHF, abnormal cardiac exam or history of
             Adriamycin therapy total dose &gt; 400 mg/m^2)

          -  Patient is pregnant

          -  Patient is seropositive for the human immunodeficiency virus

          -  Patients with a history of seizures

          -  Patients with hypersensitivity to E.coli preparations

          -  Patients with active auto-immune disease

          -  Patients with clinically significant pulmonary disease, i.e., diffusion capacity
             corrected &lt; 60% of predicted; patients with pulmonary problems should be evaluated
             with appropriate pulmonary studies and/or consult

          -  Patients with a history of CNS lesion (brain or carcinoid meningitis)

          -  Patients with significant active infection precluding transplant

          -  Patients who have had more than one prior chemotherapy regimen for stage IV disease or
             a prior transplant for any stage disease

          -  Patients who have had CD34+ selection of their PBSC products

          -  Patients will not receive IL-2/GM-CSF therapy if they:

          -  Are &gt; 100 days from transplant

          -  Have documented disease progression after transplant

          -  Have an active infection

          -  Manifested cardiac complications during the initial transplant period, including
             arrhythmias (that required therapy), congestive heart failure, angina, myocardial
             infarct, or decreased LVEF to &lt; 45%

          -  Currently have pericardial effusions, pleural effusions or ascites

          -  Manifested pulmonary toxicity during the initial transplant period and have a
             diffusion capacity corrected =&lt; 60%

          -  Are on steroids

          -  Currently have a Grade 3 toxicity from BuMelTT

          -  If the patient does not wish to receive the therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leona A Holmberg</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/Puget Sound Oncology Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <results_first_submitted>April 10, 2017</results_first_submitted>
  <results_first_submitted_qc>April 10, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 17, 2017</results_first_posted>
  <last_update_submitted>June 16, 2017</last_update_submitted>
  <last_update_submitted_qc>June 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fred Hutchinson Cancer Research Center</investigator_affiliation>
    <investigator_full_name>Leona Holmberg</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms, Male</mesh_term>
    <mesh_term>Inflammatory Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>TX/Maintenance Therapy for Stage IIIB/IV Breast Cancer</title>
          <description>See Detailed Description.
tamoxifen citrate: Given orally
busulfan: Given orally
thiotepa: Given IV
melphalan: Given IV
aldesleukin: Given SC
sargramostim: Given SC
peripheral blood stem cell transplantation: Undergo autologous peripheral blood stem cell infusion
radiation therapy: May undergo radiotherapy after completion of IL-2/GM-CSF</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Refused Post-Transplant Immunotherapy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of insurance clearance</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen fail</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TX/Maintenance Therapy for Stage IIIB/IV Breast Cancer</title>
          <description>See Detailed Description.
tamoxifen citrate: Given orally
busulfan: Given orally
thiotepa: Given IV
melphalan: Given IV
aldesleukin: Given SC
sargramostim: Given SC
peripheral blood stem cell transplantation: Undergo autologous peripheral blood stem cell infusion
radiation therapy: May undergo radiotherapy after completion of IL-2/GM-CSF</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Event-free Survival</title>
        <description>Event-free survival of patients treated for inflammatory (Stage IIIb) and responsive stage IV breast cancer with BUMELTT and PBSC support and low dose immunotherapy with IL2 and GM-CSF.</description>
        <time_frame>11 years</time_frame>
        <population>Study-wide, 20 patients out of 50 have event-free survival.</population>
        <group_list>
          <group group_id="O1">
            <title>TX/Maintenance Therapy for Stage IIIB/IV Breast Cancer</title>
            <description>See Detailed Description.
tamoxifen citrate: Given orally
busulfan: Given orally
thiotepa: Given IV
melphalan: Given IV
aldesleukin: Given SC
sargramostim: Given SC
peripheral blood stem cell transplantation: Undergo autologous peripheral blood stem cell infusion
radiation therapy: May undergo radiotherapy after completion of IL-2/GM-CSF</description>
          </group>
        </group_list>
        <measure>
          <title>Event-free Survival</title>
          <description>Event-free survival of patients treated for inflammatory (Stage IIIb) and responsive stage IV breast cancer with BUMELTT and PBSC support and low dose immunotherapy with IL2 and GM-CSF.</description>
          <population>Study-wide, 20 patients out of 50 have event-free survival.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stage IIIB Disease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage IV Disease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival of patients treated for inflammatory (Stage IIIb) and responsive stage IV breast cancer with BUMELTT and PBSC support and low dose immunotherapy with IL2 and GM-CSF.</description>
        <time_frame>11 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TX/Maintenance Therapy for Stage IIIB/IV Breast Cancer</title>
            <description>See Detailed Description.
tamoxifen citrate: Given orally
busulfan: Given orally
thiotepa: Given IV
melphalan: Given IV
aldesleukin: Given SC
sargramostim: Given SC
peripheral blood stem cell transplantation: Undergo autologous peripheral blood stem cell infusion
radiation therapy: May undergo radiotherapy after completion of IL-2/GM-CSF</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival of patients treated for inflammatory (Stage IIIb) and responsive stage IV breast cancer with BUMELTT and PBSC support and low dose immunotherapy with IL2 and GM-CSF.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Toxicity of a Combination of Low-dose IL-2 and GM-CSF</title>
        <description>IL-2/GM-CSF toxicity assessed using the NCI Toxicity Criteria. Toxicity was defined as any grade 2, 3, 4 or 5 CNS (except grade 0-3 malaise and fatigue) toxicity; any grade 3, 4, or 5 non-CNS or non-hematological toxicity (except grade 0-3 bilirubin); or any grade 4 or 5 hematological toxicity.</description>
        <time_frame>16 Weeks</time_frame>
        <population>28 (56%) of 50 patients started IL-2/GM-CSF immunotherapy. Stopping rules were not met for this study.</population>
        <group_list>
          <group group_id="O1">
            <title>TX/Maintenance Therapy for Stage IIIB/IV Breast Cancer</title>
            <description>See Detailed Description.
tamoxifen citrate: Given orally
busulfan: Given orally
thiotepa: Given IV
melphalan: Given IV
aldesleukin: Given SC
sargramostim: Given SC
peripheral blood stem cell transplantation: Undergo autologous peripheral blood stem cell infusion
radiation therapy: May undergo radiotherapy after completion of IL-2/GM-CSF</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Toxicity of a Combination of Low-dose IL-2 and GM-CSF</title>
          <description>IL-2/GM-CSF toxicity assessed using the NCI Toxicity Criteria. Toxicity was defined as any grade 2, 3, 4 or 5 CNS (except grade 0-3 malaise and fatigue) toxicity; any grade 3, 4, or 5 non-CNS or non-hematological toxicity (except grade 0-3 bilirubin); or any grade 4 or 5 hematological toxicity.</description>
          <population>28 (56%) of 50 patients started IL-2/GM-CSF immunotherapy. Stopping rules were not met for this study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>BUMELTT toxicity assessed day -8 through day 100 using the Bearman Toxicity Criteria, Grades 3 and 4. IL-2/GM-CSF toxicity over 16 weeks will be assessed using the NCI Toxicity Criteria, Grades 3 and 4.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>TX/Maintenance Therapy for Stage IIIB/IV Breast Cancer</title>
          <description>See Detailed Description.
tamoxifen citrate: Given orally
busulfan: Given orally
thiotepa: Given IV
melphalan: Given IV
aldesleukin: Given SC
sargramostim: Given SC
peripheral blood stem cell transplantation: Undergo autologous peripheral blood stem cell infusion
radiation therapy: May undergo radiotherapy after completion of IL-2/GM-CSF</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Prolonged hospitalization for post-transplant complications</sub_title>
                <description>Transplant toxicity.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Emboli</sub_title>
                <description>IL-2/GM-CSF toxicity.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Myelosuppression</sub_title>
                <description>Toxicity to transplant therapy. No deaths in 1st 100 days post-transplant.</description>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hematologic</sub_title>
                <description>Toxicity to IL-2/GM-CSF Therapy. No deaths on therapy.</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <description>Toxicity to transplant therapy. No deaths in 1st 100 days post-transplant.</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <description>Toxicity to IL-2/GM-CSF Therapy. No deaths on therapy.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Leona A. Holmberg</name_or_title>
      <organization>Fred Hutchinson Cancer Research Center</organization>
      <phone>206-667-6447</phone>
      <email>lholmber@fredhutch.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

